Hialeah Nursing And Rehabilitation Center | |
190 W 28th Street, Hialeah, Florida 33010 | |
(305) 885-2437 | |
Name | Hialeah Nursing And Rehabilitation Center |
---|---|
Location | 190 W 28th Street, Hialeah, Florida |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 276 |
Occupancy Rate | 65.8% |
Medicare ID (CCN) | 105803 |
Legal Business Name | Hialeah Enterprise, Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1437813185 |
Organization Name | TH OPCO LLC |
Doing Business As | THE TERRACE OF HIALEAH |
Address | 190 W 28th St, Hialeah, FL 33010 |
Phone Number | 386-255-1054 |
News Archive
Retractable Technologies, Inc., a leading maker of safety needle devices, announced that a final judgment and permanent injunction were entered March 4, 2010 in the litigation of Retractable Technologies, Inc. v. OMI (Occupational & Medical Innovations Limited, an Australian company).
Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.
People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.
Wearing a crash helmet is essential to a motorcyclist's safety but could it actually be harming their health and affecting their riding?
› Verified 5 days ago
NPI Number | 1790846079 |
Organization Name | HIALEAH ENTERPRISE, LLC |
Doing Business As | HIALEAH NURSING AND REHABILITATION CENTER |
Address | 190 W 28th St, Hialeah, FL 33010 |
Phone Number | 305-885-2437 |
News Archive
Retractable Technologies, Inc., a leading maker of safety needle devices, announced that a final judgment and permanent injunction were entered March 4, 2010 in the litigation of Retractable Technologies, Inc. v. OMI (Occupational & Medical Innovations Limited, an Australian company).
Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.
People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.
Wearing a crash helmet is essential to a motorcyclist's safety but could it actually be harming their health and affecting their riding?
› Verified 5 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Retractable Technologies, Inc., a leading maker of safety needle devices, announced that a final judgment and permanent injunction were entered March 4, 2010 in the litigation of Retractable Technologies, Inc. v. OMI (Occupational & Medical Innovations Limited, an Australian company).
Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.
People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.
Wearing a crash helmet is essential to a motorcyclist's safety but could it actually be harming their health and affecting their riding?
› Verified 5 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $975 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.42 | 14.46 |
Percentage of long-stay residents who lose too much weight | 10.14 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 85.94 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.38 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 3.96 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 0.55 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 9.09 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.32 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 5.04 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 35.06 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 23.67 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 13.86 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |